Literature DB >> 1360805

Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein.

G Antonelli1, O Turriziani, M Cianfriglia, E Riva, G Dong, A Fattorossi, F Dianzani.   

Abstract

Resistance of tumor cells to the antigrowth activity of several cytotoxic compounds has been associated with the expression of the so-called multidrug resistance protein or P-glycoprotein. This article addresses the question whether the expression of such protein could also affect the sensitivity of HIV to AZT. Our data indicate that this possibility does exist. In fact, multidrug-resistant CEM VBL100 cells, which express high levels of P-glycoprotein, are less sensitive to both the antiproliferative activity and the antiviral action of AZT. Additionally, our data suggest that this phenomenon is specifically mediated by P-glycoprotein since trifluoroperazine, which is known to circumvent multidrug resistance due to the action on P-glycoprotein, increases the intracellular accumulation of AZT and affects the sensitivity of HIV to AZT. Although the biological and clinical significance of these observations has still to be established, this study suggests that cellular factors, other than virus itself, should be taken into account to address the phenomenon of drug resistance of HIV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360805     DOI: 10.1089/aid.1992.8.1839

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?

Authors:  O Turriziani; P Di Marco; G Antonelli; F Dianzani
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy.

Authors:  Chiara Agrati; Fabrizio Poccia; Simone Topino; Pasquale Narciso; Cinzia Selva; Leopoldo Paolo Pucillo; Gianpiero D'Offizi; Guido Antonelli; Francesca Bellomi; Ombretta Turriziani; Federica Bambacioni
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

Review 3.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

4.  The impact of host pharmacogenetics on antiretroviral drug disposition.

Authors:  Andrew Owen
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

5.  Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Authors:  Erin Burgunder; John K Fallon; Nicole White; Amanda P Schauer; Craig Sykes; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

6.  Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT.

Authors:  Y Sai; T Nishimura; S Shimpo; T Chishu; K Sato; N Kose; T Terasaki; C Mukai; S Kitagaki; N Miyakoshi; Y-S Kang; E Nakashima
Journal:  Pharm Res       Date:  2008-03-12       Impact factor: 4.200

7.  Antiretroviral Penetration and Drug Transporter Concentrations in the Spleens of Three Preclinical Animal Models and Humans.

Authors:  Aaron S Devanathan; John K Fallon; Nicole R White; Amanda P Schauer; Brian Van Horne; Kimberly Blake; Craig Sykes; Martina Kovarova; Lourdes Adamson; Leila Remling-Mulder; Paul Luciw; J Victor Garcia; Ramesh Akkina; Jason R Pirone; Philip C Smith; Angela D M Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 8.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

9.  Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11.

Authors:  O Turriziani; J D Schuetz; F Focher; C Scagnolari; J Sampath; M Adachi; F Bambacioni; E Riva; G Antonelli
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

Review 10.  P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

Authors:  S Gupta
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.